Share on StockTwits

ICON plc (NASDAQ:ICLR) is scheduled to issue its Q1 quarterly earnings data on Wednesday, April 30th. ICON plc has set its FY14 guidance at $2.05-2.20 EPS.Investors interested in listening to the company’s conference call can do so using this link.

ICON plc (NASDAQ:ICLR) last posted its quarterly earnings results on Thursday, February 20th. The company reported $0.53 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.45 by $0.08. The company had revenue of $345.00 million for the quarter, compared to the consensus estimate of $339.86 million. On average, analysts expect ICON plc to post $2.13 EPS for the current fiscal year and $2.44 EPS for the next fiscal year.

Shares of ICON plc (NASDAQ:ICLR) opened at 39.52 on Tuesday. ICON plc has a one year low of $31.15 and a one year high of $50.00. The stock has a 50-day moving average of $45.7 and a 200-day moving average of $42.53. The company has a market cap of $2.434 billion and a price-to-earnings ratio of 25.87.

Several analysts have recently commented on the stock. Analysts at Zacks downgraded shares of ICON plc from an “outperform” rating to a “neutral” rating in a research note on Monday. They now have a $51.70 price target on the stock. On the ratings front, analysts at Credit Suisse initiated coverage on shares of ICON plc in a research note on Thursday, March 27th. They set an “outperform” rating and a $55.00 price target on the stock. Finally, analysts at Barclays raised their price target on shares of ICON plc from $48.00 to $52.00 in a research note on Monday, February 24th. They now have an “overweight” rating on the stock. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $51.86.

ICON public limited company (NASDAQ:ICLR) is a contract research organization (CRO), providing outsourced development services on a global basis to the pharmaceutical, biotechnology and medical device industries.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.